Top

Published in:

01-01-2017 | Original Article

Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions

Authors: Henning Reis, Stefanie Bertram, Leona Pott, Ali Canbay, Anja Gallinat, Hideo Andreas Baba

Published in: Pathology & Oncology Research | Issue 1/2017

Abstract

Hepatocellular Carcinoma (HCC) is a lethal cancer worldwide. Recently, the hippo signaling pathway has been implicated in tumorigenesis of HCC and other malignant tumors. Aim of the study was therefore to evaluate the hippo signaling pathway activity and its clinico-pathological associations and crosstalk in different tumor forming hepatocellular lesions (HCC, hepatocellular adenoma (HCA), focal nodular hyperplasia (FNH) and cirrhosis). A tissue micro array (TMA) from paired human tumorous and non-tumorous (NT) tissue samples of HCC (n = 92), HCA (n = 25), FNH (n = 28) and cirrhosis (n = 28; no NT) was constructed. The hippo-pathway related proteins of MST1/2, (nuclear(n)/cytoplasmic(c)) YAP and (phospho(p)) TAZ and interactors as Glypican3, RASSF1a, pAKT, pERK and pP70S6K were evaluated by immunohistochemistry (IHC). Proliferation was assessed by Ki67-IHC and apoptosis by TUNEL-technique. MST1/2- and nYAP-immunoreactivity was associated with lymph node status (p = 0.048, p = 0.001), higher grading (p = 0.012, p = 0.24) and unfavorable relapse-free survival (p = 0.004, p = 0.003). MST1/2, c/nYAP and pTAZ were significantly different between HCC/NT (p < 0.001, p = 0.029, p < 0.001, p < 0.001) and mono−/polyclonal hepatocellular lesions (HCC/HCA vs. FNH/cirrhosis; all p ≤ 0.001). Phospho-TAZ-negativity and nYAP-positivity were almost exclusively and MST1/2 exclusively detected in HCC. MST1/2 correlated with pP70S6K (p = 0.002), pERK (p = 0.042), RASSF1a-IRS (p = 0.002) and GPC3 (p < 0.001) and nYAP with GPC3 (p = 0.025), higher Ki67-indices (p = 0.016) and lower apoptosis rate (p = 0.078). MST1/2 and nYAP are unfavorable prognostic markers associated with an aggressive tumor-phenotype in HCC. Positive nYAP- and negative pTAZ-immunostaining were strong indicators of a monoclonal hepatocellular lesion. The unexpected findings for MST1/2 remain to be elucidated.

Theise ND (2014) Liver cancer. In: Stewart BW, Wild CP (eds) World cancer report 2014. International Agency for Research on Cancer, Lyon, pp. 403–412

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0 CrossRefPubMed

Harvey KF, Pfleger CM, Hariharan IK (2003) The drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114(4):457–467CrossRefPubMed

Barron DA, Kagey JD (2014) The role of the hippo pathway in human disease and tumorigenesis. Clin Transl Med 3:25. doi:10.1186/2001-1326-3-25 CrossRefPubMedPubMedCentral

Jie L, Fan W, Weiqi D, Yingqun Z, Ling X, Miao S, Ping C, Chuanyong G (2013) The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract 2013:187070. doi:10.1155/2013/187070 CrossRefPubMedPubMedCentral

Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S (2010) Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res 70(21):8517–8525. doi:10.1158/0008-5472.CAN-10-1242 CrossRefPubMedPubMedCentral

Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y, Dong J (2015) The hippo pathway effector, YAP, regulates motility, invasion and castration-resistant growth of prostate cancer cells. Mol Cell Biol 35(8):1350–1362. doi:10.1128/MCB.00102-15 CrossRefPubMedPubMedCentral

Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC (2014) KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158(1):171–184. doi:10.1016/j.cell.2014.06.004 CrossRefPubMedPubMedCentral

Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101(5):1279–1285. doi:10.1111/j.1349-7006.2010.01511.x CrossRefPubMed

10.

Hong L, Cai Y, Jiang M, Zhou D, Chen L (2015) The hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin Shanghai 47(1):46–52. doi:10.1093/abbs/gmu106 CrossRefPubMed

11.

Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ, Camargo FD (2014) Hippo pathway activity influences liver cell fate. Cell 157(6):1324–1338. doi:10.1016/j.cell.2014.03.060 CrossRefPubMedPubMedCentral

12.

Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16(5):425–438. doi:10.1016/j.ccr.2009.09.026 CrossRefPubMedPubMedCentral

13.

Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115(19):4576–4585. doi:10.1002/cncr.24495 CrossRefPubMedPubMedCentral

14.

Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q (2014) Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014:261365. doi:10.1155/2014/261365 PubMedPubMedCentral

15.

Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, Pan D (2014) A temporal requirement for hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev 28(5):432–437. doi:10.1101/gad.233676.113 CrossRefPubMedPubMedCentral

16.

Bioulac-Sage P, Balabaud C, Wanless I (2010) Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of Tumours of the digestive system. International Agency for Research on Cancer, Lyon, pp. 198–204

17.

Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, Sakamoto M, Torbeson M, Wee A (2010) Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of Tumours of the digestive system. International Agency for Research on Cancer, Lyon, pp. 205–216

18.

Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant Tumours, 7th edn. Wiley-Blackwell, Hoboken

19.

Reis H, Putter C, Megger DA, Bracht T, Weber F, Hoffmann AC, Bertram S, Wohlschlager J, Hagemann S, Eisenacher M, Scherag A, Schlaak JF, Canbay A, Meyer HE, Sitek B, Baba HA (2015) A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors. Biochim Biophys Acta 1854(6):641–650. doi:10.1016/j.bbapap.2014.10.024 CrossRefPubMed

20.

Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48(1):83–90. doi:10.1016/j.jhep.2007.08.018 CrossRefPubMed

21.

Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauder MA, Worm K, Winde G, Schmid KW, Baba HA (2007) Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 450(2):151–159. doi:10.1007/s00428-006-0342-y CrossRefPubMed

22.

Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U (2012) Deregulation of hippo kinase signalling in human hepatic malignancies. Liver Int 32(1):38–47. doi:10.1111/j.1478-3231.2011.02646.x CrossRefPubMed

23.

Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D (2015) Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the hippo kinase Cascade. Dev Cell 34(6):642–655. doi:10.1016/j.devcel.2015.08.014 CrossRefPubMedPubMedCentral

24.

Nehme NT, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, Nitschke P, Rieux-Laucat F, Lutz P, Picard C, Mahlaoui N, Fischer A, de Saint BG (2012) MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119(15):3458–3468. doi:10.1182/blood-2011-09-378364 CrossRefPubMed

25.

Rawat SJ, Chernoff J (2015) Regulation of mammalian Ste20 (Mst) kinases. Trends Biochem Sci 40(3):149–156. doi:10.1016/j.tibs.2015.01.001 CrossRefPubMedPubMedCentral

Title: Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions
Authors: Henning Reis
Stefanie Bertram
Leona Pott
Ali Canbay
Anja Gallinat
Hideo Andreas Baba
Publication date: 01-01-2017
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0079-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease

Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer

To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience

Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases

Analysis of DNA Repair Genes Polymorphisms in Breast Cancer

Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer